Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track NBIX with free AI briefings, catalyst countdowns, and dilution alerts.

NBIX · NEUROCRINE BIOSCIENCES INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$481.7M Cash on Hand

CF+ Cash Runway

Follow NBIX by email Get an email when NBIX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NBIX, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Feb 2027 · Phase 2 · Recruiting · Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dy
Registry primary completion date, not a results date
Jul 2027 · Phase 3 · Recruiting · NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjuncti
Registry primary completion date, not a results date
Jul 2027 · Phase 3 · Recruiting · NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjuncti
Registry primary completion date, not a results date
Jul 2027 · Phase 3 · Recruiting · Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Parti
Registry primary completion date, not a results date
Aug 2027 · Phase 2 · Recruiting · Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
Registry primary completion date, not a results date
Oct 2027 · Phase 3 · Recruiting · NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Valbenazine FDA approved Apr 2017 · Ingrezza	Tardive Dyskinesia	Phase 4 · NCT06107829	Withdrawn
Crinecerfont FDA approved Dec 2024 · Crenessity	Congenital Adrenal Hyperplasia	Phase 3 · NCT04806451	Active not recruiting
Chronocort	Congenital Adrenal Hyperplasia	Phase 3 · NCT03532022	Withdrawn
NBI-1065845	Major Depressive Disorder	Phase 3 · NCT06786624	Recruiting
NBI-1117568	Schizophrenia	Phase 3 · NCT06963034	Recruiting
NBI-1070770	Major Depressive Disorder	Phase 2 · NCT06267846	Completed
Plenadren	Primary Adrenal Insufficiency	Phase 2 · NCT05222152	Completed
NBIP-01435	Congenital Adrenal Hyperplasia	Phase 2 · NCT07850739	Not yet recruiting
NBI-921352	SCN8A Developmental and Epileptic Encephalopathy S	Phase 2 · NCT05226780	Terminated
NBI-827104	Epileptic Encephalopathy	Phase 2 · NCT05301894	Terminated
NBI-1117570	Schizophrenia	Phase 2 · NCT07288333	Recruiting
NBI-1117567	Alzheimer's Disease	Phase 2 · NCT07832383	Not yet recruiting
NBI-1065890	Tardive Dyskinesia	Phase 2 · NCT07365462	Recruiting
Luvadaxistat	Schizophrenia	Phase 2 · NCT05182476	Terminated
Infacort	Adrenal Insufficiency	Phase 1 · NCT03311932	Completed
DITEST	Male Hypogonadism	Phase 1 · NCT02966652	Completed

Also used in these trials (approved or third-party drugs, not NBIX's own candidates): Therapeutic Hydrocortisone, Hydrocortisone, Testosterone Undecanoate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NBIX holds $481.7M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

No operating cash burn in latest filings

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NBIX files for a raise →

Get the full NBIX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NBIX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z